CN115279752A - Taar1激动剂的盐和结晶形式 - Google Patents

Taar1激动剂的盐和结晶形式 Download PDF

Info

Publication number
CN115279752A
CN115279752A CN202180017438.9A CN202180017438A CN115279752A CN 115279752 A CN115279752 A CN 115279752A CN 202180017438 A CN202180017438 A CN 202180017438A CN 115279752 A CN115279752 A CN 115279752A
Authority
CN
China
Prior art keywords
methyl
ethyl
morpholin
pyrazole
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180017438.9A
Other languages
English (en)
Chinese (zh)
Inventor
科尔斯滕·安德里亚·格雷塞尔
乌尔斯·施维特
弗兰克·斯特拉瑟
弗洛伦斯·妮可·安托瓦内特·蒂克塞朗特
勒内·特鲁萨尔迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN115279752A publication Critical patent/CN115279752A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180017438.9A 2020-03-19 2021-03-17 Taar1激动剂的盐和结晶形式 Pending CN115279752A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20164069 2020-03-19
EP20164069.5 2020-03-19
PCT/EP2021/056749 WO2021185878A1 (en) 2020-03-19 2021-03-17 Salts and crystalline forms of a taar1 agonist

Publications (1)

Publication Number Publication Date
CN115279752A true CN115279752A (zh) 2022-11-01

Family

ID=69846246

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180017438.9A Pending CN115279752A (zh) 2020-03-19 2021-03-17 Taar1激动剂的盐和结晶形式

Country Status (13)

Country Link
US (1) US20230120311A1 (https=)
EP (1) EP4121428B1 (https=)
JP (2) JP2023517729A (https=)
KR (1) KR20220155575A (https=)
CN (1) CN115279752A (https=)
AU (1) AU2021238632A1 (https=)
BR (1) BR112022016746A2 (https=)
CA (1) CA3166331A1 (https=)
ES (1) ES3044409T3 (https=)
IL (1) IL294301A (https=)
MX (1) MX2022010794A (https=)
TW (1) TWI874616B (https=)
WO (1) WO2021185878A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222860A1 (zh) * 2023-04-28 2024-10-31 江苏豪森药业集团有限公司 一种吗啉杂环类化合物的盐及其制备方法和应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023323858A1 (en) * 2022-08-12 2024-11-21 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising 5-ethyl-4-methyl- n-[4-[(2 s) morpholin-2-yl]phenyl]-1h-pyrazole-3-carboxamide
CN117903050B (zh) * 2024-03-15 2024-05-17 中国药科大学 阿立哌唑共晶及其药物组合物和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO2017157873A1 (en) * 2016-03-17 2017-09-21 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024222860A1 (zh) * 2023-04-28 2024-10-31 江苏豪森药业集团有限公司 一种吗啉杂环类化合物的盐及其制备方法和应用

Also Published As

Publication number Publication date
JP2023517729A (ja) 2023-04-26
CA3166331A1 (en) 2021-09-23
EP4121428A1 (en) 2023-01-25
BR112022016746A2 (pt) 2022-10-11
WO2021185878A1 (en) 2021-09-23
KR20220155575A (ko) 2022-11-23
US20230120311A1 (en) 2023-04-20
EP4121428B1 (en) 2025-08-13
IL294301A (en) 2022-08-01
AU2021238632A1 (en) 2022-07-14
TW202140466A (zh) 2021-11-01
ES3044409T3 (en) 2025-11-26
EP4121428C0 (en) 2025-08-13
TWI874616B (zh) 2025-03-01
MX2022010794A (es) 2022-09-27
JP2025166092A (ja) 2025-11-05

Similar Documents

Publication Publication Date Title
CN103958469B (zh) 一种新的普利多匹定盐酸盐多晶型形态
JP6995043B2 (ja) リジン特異的デメチラーゼ－１の阻害剤を含む組成物
JP2025166092A (ja) Ｔａａｒ１アゴニストの塩形態および結晶形態
WO2019191620A1 (en) Crystalline forms of modulators of cftr
JP5997162B2 (ja) アプレピタントｌ−プロリン組成物および共結晶
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
JP2024517608A (ja) 結晶性カルバゾール誘導体
US20230322657A1 (en) Crystalline edg-2 receptor antagonist and methods of making
HK40074347A (en) Salts and crystalline forms of a taar1 agonist
US20140275268A1 (en) Novel solid forms of tacedinaline
WO2024037422A1 (en) Crystalline forms of a glucosylceramide synthase inhibitor and uses thereof
EP4553078A1 (en) 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one and crystal of salt thereof
CN110218209A (zh) 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用
US20230312551A1 (en) Salt of 2-(substituted pyrimidinyl) thiazole carboxamide compound, and composition and use thereof
TW202506661A (zh) 一種酪氨酸激酶抑制劑的可藥用鹽、結晶形式及其製備方法
WO2023153422A1 (ja) シクロヘキセノン化合物の結晶形
KR20250152557A (ko) 결정질 카바졸 유도체 및 이의 제조 방법
HK40077679A (en) Crystalline compounds
KR20250024987A (ko) 4-[(5-클로로피리딘-2-일)메톡시]-1-[3-(프로판-2-일)-1H,2H,3H,4H,5H-[1,4]디아제피노[1,7-a]인돌-9-일]-1,2-디하이드로피리딘-2-온의결정질 형태 및 이의 염, 이의 제조 방법 및 용도
HUE027309T2 (en) Crystalline solvates of 6- (Piperidin-4-ylix) -2H-isoquinolin-1-one hydrochloride
WO2019142111A1 (en) Salt forms of an oxazine derivative bace inhibitor
WO2018130226A1 (zh) 利奥西呱的新晶型及其制备方法和用途
CN110317159A (zh) 一种Lu AE58054的新晶型及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40074347

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination